US Patent Issued to North Carolina State University on Dec. 2 for "Chromosomal assessment to differentiate histiocytic malignancy from lymphoma and hemangiosarcoma in dogs" (North Carolina Inventor)

ALEXANDRIA, Va., Dec. 2 -- United States Patent no. 12,486,541, issued on Dec. 2, was assigned to North Carolina State University.

"Chromosomal assessment to differentiate histiocytic malignancy from lymphoma and hemangiosarcoma in dogs" was invented by Matthew Breen (Apex, N.C.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This invention relates generally to the discovery of an improved method to differentiate histiocytic malignancy from lymphoma or hemangiosarcoma in dogs."

The patent was filed on Nov. 2, 2022, under Application No. 17/979,538.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%...